‘There is no way to stop this’: ‘Biotech Barbie’ Cathy Tie on her mission to genetically modify babies
By Jenny Kleeman,
The Guardian
| 05. 30. 2026
The Canadian entrepreneur has always pushed the boundaries of gene editing, once attempting to turn horses into unicorns. Now she is set on modifying human embryos – something her controversial ex-husband was jailed for doing.
On a Friday evening in late April, Cathy Tie, the Canadian serial entrepreneur and self-styled “Biotech Barbie”, is centre stage at New York City’s famous Carnegie Hall, performing Saint-Saens’ Piano Concerto No 2 on a gleaming Steinway grand piano, accompanied by an orchestra. Her floor-length pink tulle gown shimmers with gold sequins; her dark hair cascades in waves over her caped shoulders. The music is passionate, but Tie’s expression is impassive. Her eyes dart between the piano keys and the sheet music in a flurry of concentration, but the rest of her face is totally still. She isn’t lost in the music; she’s focused on the job.
After the last notes ring out, Tie stands up and breaks into a tight smile and a brief bow before walking off stage, only to immediately return to receive the slightly awkward Happy Birthday sung by everyone in the orchestra and auditorium. This is Tie’s 30th birthday party. She has hired Carnegie Hall to mark the occasion. And, as I discover at the cocktail afterparty, most of the people invited to this performance...
Related Articles
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Rebecca Roberts, The Scientist | 05.19.2026
Scientists have had prenatal gene therapy in their sights for decades; by treating the fetus in utero, they can potentially prevent the long-term damage caused by severe, early-onset genetic disorders. Despite its success in preclinical studies, the method has...
By Moe Alsumidaie, The Clinical Trial Vanguard | 05.26.2026
Picture the moment a gene therapy trial’s safety monitor pulls up a patient record — years after the last dose, long after the trial team has dissolved and the CRO contract has closed — and finds a tumor. The vector...
By Gina Kolata, The New York Times | 05.25.2026
In a small, preliminary study, an experimental gene-editing treatment dramatically lowered cholesterol levels, perhaps permanently, after just one infusion, scientists reported on Monday.
If confirmed in larger studies, researchers hope the findings may lead to a one-and-done way to prevent...